Johnson & Johnson consumer segment sales up for Q1
18 Apr '07
3 min read
"We are delighted to add the Pfizer Consumer Healthcare and Conor Medsystems businesses to the Johnson & Johnson family of companies. Our strategy of being broadly-based continues to serve us well and is one of the keys to our consistent long-term performance."
Worldwide Consumer segment sales of $3.5 billion for the first quarter represented a 48.5% increase over the prior year with operational growth of 45.7% and a positive impact from currency of 2.8%. Domestic sales increased 41.7%, while international sales increased 54.9% (49.4% from operations and 5.5% from currency).
On a pro-forma basis, including the net impact of the acquisition of Pfizer Consumer Healthcare in both periods, worldwide sales for the Consumer segment increased 6.7% operationally.
Sales growth in the combined business reflects the strong performance of McNeil Consumer's reformulated TYLENOL over-the-counter upper respiratory products; LISTERINE antiseptic mouthrinse; the skin care lines of AVEENO and CLEAN & CLEAR; BENADRYL allergy products; ROGAINE hair regrowth treatment, and VISINE eye care products.
Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 250 Johnson & Johnson operating companies employ approximately 121,000 men and women in 57 countries and sell products throughout the world.